STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

A Novartis Lp(a) drug lowered a risk marker for cardiovascular disease but did not lower the chance of heart attack or stroke, according to a report discussed at the AHA conference. The failure raises questions about the company's cardiovascular strategy.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.